ClearPoint Neuro Announces FDA Clearance for ClearPoint Prism™ Neuro Laser Therapy System
September 23, 2022 02:45 ET | ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer
September 20, 2022 16:05 ET | ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Announces FDA Clearance for Software Version 2.1
September 19, 2022 16:13 ET | ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint-13169-Final-Logo-CMYK jpg.jpg
ClearPoint Neuro Reports Second Quarter 2022 Results
August 09, 2022 16:15 ET | ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint-13169-Final-Logo-CMYK jpg.jpg
ClearPoint Neuro Announces FDA Clearance for ClearPoint Maestro™ Brain Model
August 09, 2022 16:05 ET | ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint-13169-Final-Logo-CMYK jpg.jpg
ClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs
August 08, 2022 16:05 ET | ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint-13169-Final-Logo-CMYK jpg.jpg
ClearPoint Neuro to Announce Second Quarter 2022 Results August 9, 2022
July 26, 2022 16:05 ET | ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint-13169-Final-Logo-CMYK jpg.jpg
ClearPoint Neuro félicite son partenaire PTC Therapeutics pour l'obtention de l'autorisation de mise sur le marché par la Commission européenne pour Upstaza™ - premier traitement modificateur de la maladie pour le déficit en AADC
July 22, 2022 12:22 ET | ClearPoint Neuro, Inc.
La première thérapie génique approuvée pour une perfusion directe dans le cerveau sera administrée avec la canule neurologique SmartFlow® de ClearPoint SOLANA BEACH, Californie, 22 juill. 2022 ...
ClearPoint-13169-Final-Logo-CMYK jpg.jpg
ClearPoint Neuro beglückwünscht Partner PTC Therapeutics für den Erhalt der Marktzulassung durch die Europäische Kommission für Upstaza™ - die erste krankheitsmodifizierende Behandlung von AADC-Mangel
July 22, 2022 12:22 ET | ClearPoint Neuro, Inc.
Die erste zur direkten Infusion in das Gehirn zugelassene Gentherapie wird mit der SmartFlow® Neurokanüle von ClearPoint verabreicht SOLANA BEACH, Kalifornien, July 22, 2022 (GLOBE NEWSWIRE) --...
ClearPoint-13169-Final-Logo-CMYK jpg.jpg
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Commission for Upstaza™ - First Disease-Modifying Treatment for AADC Deficiency
July 21, 2022 16:20 ET | ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...